Stimulating and blocking thyroid-stimulating hormone (TSH) receptor autoantibodies from patients with Graves' disease and autoimmune hypothyroidism have very similar concentration, TSH receptor affinity, and binding sites.

OBJECTIVE The distinct biological properties of TSH receptor (TSH-R) autoantibodies (TRAbs) from patients with Graves' disease (GD) are yet unexplained on the molecular level. Here we compare serum concentration, affinity to the TSH-R, and binding sites on the TSH-R of stimulating (TSAb) and blocking (TBAb) TRAbs. METHODS AND PATIENTS Four-step affinity purification using human recombinant TSH-R was performed with 22 TRAb-positive sera from GD patients (11 with only TSAb and 11 with only TBAb) and five control sera. Antibody concentration, TSH binding inhibition (TBII), and TSAb/TBAb activity of the purified TRAb were assessed. Labeled purified TRAbs were used for displacement studies with TRAb and an additional 30 patients and 10 control sera. RESULTS TRAbs could be purified to 80-93% purity with recovery of the TBII and TSAb and TBAb activity. No TRAbs could be purified from healthy individuals. The mean +/- SD concentration of TRAb was 17.3 +/- 5.4 microg/IU for the TSAb sera (range, 9.6-25.9) and 18.2 +/- 8.5 microg/IU for the TBAb sera (range, 4.6-29.2), respectively (P = 0.79). Affinity was in the picomolar range for both TRAb subtypes with mean +/- sd dissociation constant of 167 +/- 109 pM (60-410 pM) for TSAb and 253 +/- 132 pM (80-410 pM) for TBAb (P = 0.12). Purified and labeled TSAb and TBAb showed a very similar binding pattern to the TSH-R in displacement studies with unlabeled TSAb/TBAb or unpurified patients sera, indicating binding sites on the TSH-R in close proximity to each other. CONCLUSION TSAbs and TBAbs in the serum of patients with GD have similar characteristics. They are of low concentration with high affinity and have also similar binding epitopes on the TSH-R.

[1]  T. Blundell,et al.  Analysis of the thyrotropin receptor-thyrotropin interaction by comparative modeling. , 2004, Thyroid : official journal of the American Thyroid Association.

[2]  A. Bergmann,et al.  Generation of a mouse monoclonal TSH receptor antibody with stimulating activity. , 2002, Biochemical and biophysical research communications.

[3]  B. Rapoport,et al.  Evidence for a simplified view of autoantibody interactions with the thyrotropin receptor. , 2002, Thyroid : official journal of the American Thyroid Association.

[4]  Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves' disease. , 1999, The Journal of clinical endocrinology and metabolism.

[5]  W. Scherbaum,et al.  Detecting TSH-receptor antibodies with the recombinant TBII assay: technical and clinical evaluation. , 2000, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[6]  L. Pardo,et al.  Glycoprotein hormone receptors: determinants in leucine‐rich repeats responsible for ligand specificity , 2003, The EMBO journal.

[7]  N. Morgenthaler,et al.  Delineation of the discontinuous-conformational epitope of a monoclonal antibody displaying full in vitro and in vivo thyrotropin activity. , 2004, Molecular endocrinology.

[8]  N. Morgenthaler,et al.  A coated tube assay for the detection of blocking thyrotropin receptor autoantibodies. , 2004, The Journal of clinical endocrinology and metabolism.

[9]  S. Wodak,et al.  Modeling of the three-dimensional structure of proteins with the typical leucine-rich repeats. , 1995, Structure.

[10]  N. Morgenthaler,et al.  Affinity purification and diagnostic use of TSH receptor autoantibodies from human serum , 2003, Molecular and Cellular Endocrinology.

[11]  K. Eguchi,et al.  Dissecting linear and conformational epitopes on the native thyrotropin receptor. , 2004, Endocrinology.

[12]  J. Sanders,et al.  Thyroid-stimulating monoclonal antibodies. , 2002, Thyroid : official journal of the American Thyroid Association.

[13]  B. Rapoport,et al.  Affinity-enrichment of thyrotropin receptor autoantibodies from Graves' patients and normal individuals provides insight into their properties and possible origin from natural antibodies. , 2004, The Journal of clinical endocrinology and metabolism.

[14]  N. Morgenthaler,et al.  Antibodies to TSH‐receptor in thyroid autoimmune disease interact with monoclonal antibodies whose epitopes are broadly distributed on the receptor , 2004, Clinical and experimental immunology.

[15]  B. Rapoport,et al.  The Thyrotropin (TSH)-Releasing Hormone Receptor: Interaction with TSH and Autoantibodies , 1998 .

[16]  D. Russo,et al.  Binding domains of stimulatory and inhibitory thyrotropin (TSH) receptor autoantibodies determined with chimeric TSH-lutropin/chorionic gonadotropin receptors. , 1991, The Journal of clinical investigation.

[17]  B. Smith,et al.  Human monoclonal thyroid stimulating autoantibody , 2003, The Lancet.

[18]  Eng,et al.  Differences in the levels of TSH‐binding inhibitor immunoglobulins in goitrous and agoitrous autoimmune thyroiditis after twelve months of l‐thyroxine therapy , 1999, Clinical endocrinology.

[19]  Wayne A. Hendrickson,et al.  Structure of human follicle-stimulating hormone in complex with its receptor , 2005, Nature.

[20]  G. Scatchard,et al.  THE ATTRACTIONS OF PROTEINS FOR SMALL MOLECULES AND IONS , 1949 .

[21]  W. Scherbaum,et al.  Application of a Bioassay with CHO Cells for the Routine Detection of Stimulating and Blocking Autoantibodies to the TSH-Receptor , 1998, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[22]  R. Paschke,et al.  Identification of a Novel Epitope in the Thyroid-stimulating Hormone Receptor Ectodomain Acting as Intramolecular Signaling Interface*[boxs] , 2004, Journal of Biological Chemistry.

[23]  M. Parmentier,et al.  Stable expression of the human TSH receptor in CHO cells and characterization of differentially expressing clones. , 1990, Biochemical and biophysical research communications.

[24]  S. Cornelis,et al.  Purification and characterization of a soluble bioactive amino-terminal extracellular domain of the human thyrotropin receptor. , 2001, Biochemistry.

[25]  T. Ando,et al.  A monoclonal thyroid-stimulating antibody. , 2002, The Journal of clinical investigation.

[26]  T. Akamizu,et al.  Use of thyrotropin receptor (TSHR) mutants to detect stimulating TSHR antibodies in hypothyroid patients with idiopathic myxedema, who have blocking TSHR antibodies. , 1993, The Journal of clinical endocrinology and metabolism.

[27]  D. Lütkemeyer,et al.  Development of Serum‐Free Bioreactor Production of Recombinant Human Thyroid Stimulating Hormone Receptor , 2000, Biotechnology progress.

[28]  B. Rapoport,et al.  Engineering the Human Thyrotropin Receptor Ectodomain from a Non-secreted Form to a Secreted, Highly Immunoreactive Glycoprotein That Neutralizes Autoantibodies in Graves’ Patients’ Sera* , 1997, The Journal of Biological Chemistry.